Four-day Intensive Treatment Versus Standard Cognitive Behavioral Therapy for Adults With Obsessive-compulsive Disorder

Obsessive-Compulsive Disorder Clinical Trial

Official title:

Four-day Intensive Treatment Versus Standard Cognitive Behavioral Therapy for Adults With Obsessive-compulsive Disorder: a Single-blind, Randomized Controlled Non-inferiority Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05608278
• Other study ID #: OCD - B4DT vs standard CBT
• Status: Recruiting
• Phase: N/A
• Start date: November 17, 2022
• Est. completion date: August 30, 2025

Study information

• Verified date: March 2023
• Source: Karolinska Institutet
• Contact: Christian Rück, PhD
• Phone: +46704843392
• Email: christian.ruck[@]ki.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare a novel, condensed version of cognitive behavioral therapy (Bergen 4-Day Treatment, B4DT) to the gold standard psychological treatment (gold-standard CBT) for obsessive compulsive disorder (OCD). The main question it aims to answer is: • Is B4DT non-inferior to standard cognitive behavioral therapy (CBT) with regard to OCD symptoms 14 weeks after treatment start? Adult patients with obsessive compulsive disorder will be randomly assigned to receive either gold standard CBT one to two times per week for 14 weeks, or 4 days of B4DT during one week.

Description:

Obsessive-compulsive disorder is a persistent and disabling psychiatric disorder. Individual cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) is an effective treatment for OCD and is recommended as a first-line intervention. However, patients need to remain in treatment for several months and even after that, around 50% remain symptomatic despite this lengthy treatment. In response to this, a novel, condensed version of CBT, B4DT, has been developed. B4DT has shown promising results in several uncontrolled trials and one randomized controlled trial with inactive control, however it has yet to be directly compared to gold-standard individual CBT. This single blind, randomized controlled trial with 120 patients (60 per arm) will compare B4DT to gold standard CBT. The primary outcome is the blind-rater administered Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The investigators hypothesize that B4DT will be non-inferior to gold standard CBT 14 weeks after treatment start. The non-inferiority margin is set at 4 points on the Y-BOCS. Secondary outcomes are cost effectiveness, speed of response, response and remission rates, dropout rate, and negative effects. The investigators hypothesise that participants that receive B4DT will improve faster than patients that receive standard CTB, but for the rest of the secondary outcomes, the investigators have no directed hypotheses. A more detailed preregistration, and all analysis scripts, are available at Open Science Framework (https://osf.io/w5bfp/).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: August 30, 2025
• Est. primary completion date: August 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years of age.

2. Primary diagnosis of OCD according to the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5).

3. Clinician-rated Y-BOCS score of = 16

4. Written informed consent.

5. To be willing and able to attend treatment at any one of the two treatment clinics, regardless of the clinic where the initial assessment took place (the two clinics are located at different locations in Stockholm, about 20 Km apart).

6. Be fluent in Swedish.

Exclusion Criteria:

1. Other psychological treatment for OCD planned during trial period.

2. Completed CBT with ERP for OCD in the last 12 months.

3. Changes in psychotropic medication within the last 2 months.

4. Bipolar disorder.

5. Psychosis.

6. Alcohol or substance dependence.

7. Organic brain disorder.

8. Hoarding disorder or OCD with primary hoarding symptoms.

9. Suicidal ideation that would warrant close monitoring.

Related Conditions & MeSH terms

• Disease
• Obsessive-Compulsive Disorder

Intervention

Behavioral:
• Bergen 4-Day Treatment (B4DT)
Novel CBT treatment
• Gold standard cognitive behavioral therapy (gold standard CBT)
Gold standard CBT treatment

Locations

Country	Name	City	State
Sweden	Psykiatri Nordväst, Stockholms Läns Sjukvårdsområde (SLSO), Stockholms Läns Landsting	Stockholm
Sweden	Psykiatri sydväst	Stockholm

Sponsors (2)

Lead Sponsor	Collaborator
Karolinska Institutet	Helse-Bergen HF

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Patient Exposure/Response Prevention Adherence Scale (PEAS)	Measures the patient's between-session adherence to the therapist's exposure and response prevention instructions. The scale has three subscales: exposure assignments attempted, the quality of exposure assignments attempted, and the percentage of rituals resisted between session. Each subscale ranges from 0 to 100%, high scores represent better adherence.	Gold standard CBT: week 4, 7, and 15. B4DT: week 3.
Other	Yale-Brown Obsessive Compulsive Scale-Self-Rated (Y-BOCS-SR)	Self rated version of the primary outcome that measures severity of obsessions and compulsions. It consists of 10 items rated on a 5-point Likert scale (0 to 4) with higher scores denoting greater symptom severity.	Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Other	Montgomery-Åsberg Depression Rating Scale-Self-Rated (MADRS-S)	Measures symptom severity of depression. MADRS is a 9-item depressive symptoms scale where the symptoms are assessed on a 7-point likert scale from no symtoms to very high severity. The total score ranges from 0 to 54 with higher score indicating more severe problems.	Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Other	Work and Social Adjustment Scale (WSAS)	Measures impairment in functioning. Scores range from 0-40, with lower scores representing better functioning.	Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Other	Credibility/Expectancy Questionnaire (CEQ)	Measures treatment expectancy and rationale credibility. The CEQ is a 5-item measure of the treatment's credibility and the patients' expectations. The patients assess each domain on a 11-point likert scale (scored 0-10), with a total score ranging between 0-50 where higher score indicates higher credibility and higher expectations.	Week 2
Other	Working Alliance Inventory-Short Form Revised (WAI-SR)	Measures the therapeutic alliance in therapy. The WAI-SR is a 12-item measure of the patient's experience of their working alliance with the therapist. The patients assess each item on a 7-point likert scale (scored 0-6), with a total score ranging between 0-72 where higher score indicates higher better working alliance according to the patient.	Week 2
Other	Obsessive-Compulsive Inventory-Revised (OCI-R)	Self-rating scale that measures the severity and type of symptoms of OCD. The Obsessive-Compulsive Inventory-Revised (OCI-R) has 18 items. Each item is scored on a 5 point scale from 0 to 4. Total score ranges from 0 to 72, higher scores represent more severe OCD.	Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Primary	Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), clinician-administered	Clinician administered scale that measures the severity of obsessions and compulsions. Ten questions, with scores ranging from 0 to 4 (most severe), address time, interference, distress, resistance and control over obsessions and compulsions (total score range from 0 to 40).	Change from baseline to 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Secondary	Clinical Global Impression - Severity (CGI-S)	Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.	14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Secondary	Clinical Global Impression - Improvement (CGI-I)	Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.	14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Secondary	Dropout rate in both arms	A dropout will be defined as a patient in the B4DT arm that participates in less than 1.5 full days at the clinic, or a patient in the gold standard CBT arm that participates in less than 8 CBT sessions.	Gold standard CBT: week 15. B4DT: week 3.
Secondary	Treatment Inventory of Costs in Psychiatric Patients (TIC-P)	Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder. The TIC-P questionnaire measures costs in two dimensions: use of health resources and loss of productivity. Lower cost is better.	Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Secondary	Negative Effects Questionnaire (NEQ)	Self-rated questionnaire on negative effects. It contains 32 items that are scored on a five point Likert-scale (0-4) and differentiates between negative effects that are attributed to treatment and those possibly caused by other circumstances. The total score of the NEQ ranges from 0 to 80 points, a higher score reflects more negative effects.	14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups
Secondary	Assessing Quality of Life 6 Dimensions (AQoL-6D)	Used to assess cost-effectiveness. 20 questions that assess different aspects of quality of life. The AQoL provides a utility score that ranges from 1.00 (full health) to 0.00 (death-equivalent health states) to -0.04 (health states worse than death).	Change from baseline to 14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups